StonvexLoading…
StonvexStonvexStonvexCore line items from BG's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q3 2026 (Est.) Expected 2026-07-28 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $23.64B | $4.66B | $16.94B | $12.06B | $7.68B |
Operating Income | Not available | $61.00M | $1.13B | $1.05B | $778.00M |
Net Income | Not available | $68.00M | $816.00M | $166.00M | $354.00M |
EPS (Diluted) | $1.99 | $0.35 | $4.91 | $0.84 | $2.61 |
Total Assets | Not available | $47.58B | $44.53B | $46.30B | $31.15B |
Total Liabilities | Not available | Not available | Not available | Not available | Not available |
Cash & Equivalents | Not available | $839.00M | $1.14B | $1.31B | $6.79B |
Free Cash Flow OCF − CapEx | Not available | $-877.00M | $-879.00M | $-1.69B | $-2.07B |
Shares Outstanding | Not available | 195.73M | 166.47M | 156.71M | 135.50M |